Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

<p>Evaluation of circulating CD4+ T cell subsets. (A) Changes in regulatory T cells (Tregs) during treatment compared to screening in the entire patient cohort. (B) Changes in levels of circulating CD4+ naïve (CD45RA+ CCR7+), central memory (CM; CD45RA- CCR7+), effector memory (EM; CD45RA- CCR...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
מחבר ראשי:	Dwight H. Owen (15034782) (author)
מחברים אחרים:	Brooke Benner (15054338) (author), Lai Wei (15023852) (author), Vineeth Sukrithan (15054341) (author), Ashima Goyal (15054344) (author), Ye Zhou (15054347) (author), Carly Pilcher (15054350) (author), Sheryl-Ann Suffren (15054353) (author), Gwen Christenson (15054356) (author), Nancy Curtis (15054359) (author), Megan Jukich (15054362) (author), Emily Schwarz (15054365) (author), Himanshu Savardekar (15054368) (author), Ruthann Norman (15054371) (author), Sarah Ferguson (15054374) (author), Barbara Kleiber (15054377) (author), Robert Wesolowski (8863505) (author), William E. Carson (15054380) (author), Gregory A. Otterson (15054383) (author), Claire F. Verschraegen (15054386) (author), Manisha H. Shah (15054389) (author), Bhavana Konda (15054392) (author)
יצא לאור:	2025
נושאים:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Chemotherapy Combination chemotherapy Clinical Trial Results Phase II clinical trials Endocrine-Related Cancers Immunotherapy Checkpoint blockade Lung Cancer
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

פריטים דומים